Chimerix (NASDAQ:CMRX) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report)'s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.55 and traded as high as $4.14. Chimerix shares last traded at $4.07, with a volume of 1,033,097 shares trading hands.

Analyst Ratings Changes

Several research analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Chimerix in a report on Monday, December 30th. Wedbush reaffirmed an "outperform" rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday, December 10th.

Chimerix Stock Performance

The firm has a market capitalization of $369.65 million, a price-to-earnings ratio of -4.37 and a beta of 0.36. The business has a fifty day moving average price of $2.74 and a 200 day moving average price of $1.55.

Chimerix (NASDAQ:CMRX - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.26 million. During the same quarter in the prior year, the company earned ($0.27) EPS. On average, analysts expect that Chimerix, Inc. will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Chimerix

A number of hedge funds and other institutional investors have recently bought and sold shares of CMRX. Stoneridge Investment Partners LLC boosted its stake in Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock worth $154,000 after purchasing an additional 8,134 shares during the period. Palumbo Wealth Management LLC acquired a new position in shares of Chimerix during the fourth quarter worth $221,000. Valeo Financial Advisors LLC raised its stake in shares of Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock valued at $509,000 after acquiring an additional 64,420 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after acquiring an additional 138,098 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Chimerix in the second quarter valued at approximately $137,000. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.